Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6Â Gy With Concurrent 5-FU/Mitomycin C Is Superior to HART of 77.6Â Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95-06 Randomized Phase III Trial

C-HART remains superior to HART in terms of LRC. However, this effect may be limited to oropharyngeal cancer patients.